David Nierengarten

Work

Analyst David Nierengarten works at WEDBUSH and is focused on the Healthcare sector with 468 price targets and ratings documented since 2013 spanning on 41 stocks. Analyst's average stock valuation to be materialised ratio is 54.21% with an average time for price targets to be met of 139.53 days.

Most recent stock forecast was given on YMAB, Y-mAbs Therapeutics, Inc at 31-Oct-2022.

David Nierengarten best performing recommendations are on AVRO (AVROBIO, INC).
The best stock recommendation documented was for KPTI (KARYOPHARM THERAPEUTICS INC) at 3/2/2020. The price target of $25 was fulfilled within 1 day with a profit of $2.72 (9.81%) receiving and performance score of 98.12.

Average potential price target upside

of $28.44 (26.29%) on ARGX (ARGENX SE) .
of $24.41 (13.38%) on NVCR (NOVOCURE LIMITED) .
of $22.38 (34.91%) on BPMC (BLUEPRINT MEDICINES CORPORATION) .

ANAB ARAV ARGX AVRO BEAM BLUE BPMC CDAK COGT EPZM FATE GTHX INZY ITOS KPTI MGNX MYOK NTLA NUVB NVCR ORTX STML STRO TC TCRR TPTX TSVT XNCR YMAB CDTX KNSA SRRK SWTX VYGR AGTC ARDX MRUS PRTA RARE KNTE VOR

Covered Stocks

David Nierengarten